Marion Procter

12.3k total citations · 2 hit papers
34 papers, 2.8k citations indexed

About

Marion Procter is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marion Procter has authored 34 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 17 papers in Cancer Research and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marion Procter's work include HER2/EGFR in Cancer Research (30 papers), Breast Cancer Treatment Studies (16 papers) and Peptidase Inhibition and Analysis (12 papers). Marion Procter is often cited by papers focused on HER2/EGFR in Cancer Research (30 papers), Breast Cancer Treatment Studies (16 papers) and Peptidase Inhibition and Analysis (12 papers). Marion Procter collaborates with scholars based in Belgium, Switzerland and Italy. Marion Procter's co-authors include Martine Piccart, Richard D. Gelber, Evandro de Azambuja, Thomas Suter, Mitch Dowsett, Giuseppe Viale, Brian Leyland‐Jones, David Cameron, Michael Untch and Dimitrios Zardavas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Marion Procter

31 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

2017 918 citations Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine profile →
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marion Procter Belgium	13	2.3k	926	849	683	593	34	2.8k
Maureen Murphy United States	5	2.3k 1.0×	404 0.4×	1.2k 1.4×	781 1.1×	491 0.8×	6	3.0k
Adam Knott United Kingdom	17	3.2k 1.4×	1.0k 1.1×	1.4k 1.7×	615 0.9×	984 1.7×	33	4.2k
Stanford J. Stewart United States	9	2.5k 1.1×	404 0.4×	1.5k 1.8×	778 1.1×	534 0.9×	14	3.5k
Jayantha Ratnayake United Kingdom	10	2.2k 1.0×	1.4k 1.5×	849 1.0×	100 0.1×	574 1.0×	14	2.8k
Deborah Lindquist United States	10	2.5k 1.1×	648 0.7×	812 1.0×	119 0.2×	938 1.6×	22	3.0k
Virginia McNally United Kingdom	18	2.5k 1.1×	990 1.1×	866 1.0×	102 0.1×	666 1.1×	38	3.0k
Thomas E. Seay United States	15	1.7k 0.8×	558 0.6×	231 0.3×	361 0.5×	502 0.8×	20	2.2k
Noam Pondé Belgium	19	981 0.4×	488 0.5×	212 0.2×	195 0.3×	372 0.6×	52	1.4k
Vichien Srimuninnimit Thailand	21	2.9k 1.3×	1.7k 1.8×	794 0.9×	98 0.1×	1.6k 2.6×	67	3.8k
Jutta Steinseifer Switzerland	10	990 0.4×	484 0.5×	212 0.2×	242 0.4×	495 0.8×	15	1.5k

Countries citing papers authored by Marion Procter

Since Specialization

Citations

This map shows the geographic impact of Marion Procter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Procter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Procter more than expected).

Fields of papers citing papers by Marion Procter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Procter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Procter. The network helps show where Marion Procter may publish in the future.

Co-authorship network of co-authors of Marion Procter

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Procter. A scholar is included among the top collaborators of Marion Procter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Procter. Marion Procter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Loibl, S., Carolyn J. Henry, Giovanni Tomasello, et al.. (2025). LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up. ESMO Open. 10. 105112–105112. 1 indexed citations

2.

Franzoi, Maria Alice, Marion Procter, Chris Twelves, et al.. (2022). Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial. ecancermedicalscience. 16. 1379–1379.

3.

Bines, José, Emma Clark, Claire Barton, et al.. (2021). Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer. 125(1). 38–47. 5 indexed citations

4.

Azambuja, Evandro de, Daniel Eiger, Marion Procter, et al.. (2021). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.. Journal of Clinical Oncology. 39(15_suppl). 510–510. 1 indexed citations

5.

Franzoi, Maria Alice, Marion Procter, Noam Pondé, et al.. (2021). Abstract PS7-21: Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial. Cancer Research. 81(4_Supplement). PS7–21. 1 indexed citations

6.

Bines, José, Marion Procter, Eleonora Restuccia, et al.. (2019). Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer. 20(2). 174–181.e3. 4 indexed citations

7.

Azambuja, Evandro de, Noam Pondé, Marion Procter, et al.. (2019). A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Research and Treatment. 179(1). 161–171. 40 indexed citations

8.

Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →

9.

Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. 377(2). 122–131. 918 indexed citations breakdown →

10.

Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology. 35(15_suppl). LBA500–LBA500.

11.

Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology. 35(18_suppl). LBA500–LBA500. 9 indexed citations

12.

Jackisch, C, M. Piccart, RD Gelber, et al.. (2016). Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. Cancer Research. 76(4_Supplement). PD5–1. 8 indexed citations

13.

Metzger, Otto, Evandro de Azambuja, Marion Procter, et al.. (2015). Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Research and Treatment. 155(1). 127–132. 7 indexed citations

14.

Zabaglo, Lila, Josef Rüschoff, Janine Salter, et al.. (2013). HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Annals of Oncology. 24(11). 2761–2766. 22 indexed citations

15.

Metzger, Otto, Marion Procter, Evandro de Azambuja, et al.. (2013). Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology. 31(16). 1954–1960. 30 indexed citations

16.

Azambuja, Evandro de, Marion Procter, Dominique Agbor‐Tarh, et al.. (2013). Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.. Journal of Clinical Oncology. 31(15_suppl). 525–525. 2 indexed citations

17.

Zabaglo, Lila, et al.. (2010). Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience. Cancer Research. 70(24_Supplement). PD10–1. 2 indexed citations

18.

Procter, Marion, Thomas Suter, Evandro de Azambuja, et al.. (2010). Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology. 28(21). 3422–3428. 179 indexed citations

19.

Procter, Marion, D.J. van Veldhuisen, M Muscholl, et al.. (2007). P110 Cardiac side effects in the HERceptin Adjuvant, (HERA) trial. The Breast. 16. S44–S44. 2 indexed citations

20.

Suter, Thomas, Marion Procter, Dirk J. van Veldhuisen, et al.. (2007). Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. Journal of Clinical Oncology. 25(25). 3859–3865. 399 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact